Month: September 2025

Atlanta, GA, Sept. 03, 2025 (GLOBE NEWSWIRE) — ScanTech AI Systems Inc. (the “Company” or “ScanTech AI”) (Nasdaq: STAI), a next-generation provider of AI-powered CT screening systems for aviation, customs, and critical infrastructure, today announced a consultancy agreement with FSR Group Pte. Ltd. (“FSR Capital”) to provide specialized advisory services in capital markets, Nasdaq compliance, and SEC reporting. This forward-looking initiative highlights ScanTech AI’s proactive commitment to resolving ongoing regulatory challenges, enhancing investor confidence, and positioning the Company for sustained growth in a competitive market. FSR Capital brings a team with a proven track record of success in navigating Nasdaq compliance issues for public companies, including bid price deficiencies and filing delays,...

REDWOOD CITY, Calif./BELFAST, Northern Ireland, Sept. 03, 2025 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB:BTCY), an innovative medical technology company specializing in remote cardiac monitoring solutions, and B-Secur, a leader in ECG algorithm and biosensing technology, are transforming the consumer wearables market with an enhancement to their joint cardiac monitoring platform. The device-neutral platform, which launched in early 2025 for ambulatory cardiac monitoring, will now support ECG data from consumer wearables. This advancement enables the seamless integration and review of user data collected from smartwatches, smart rings, fitness trackers, and other mobile health products within Biotricity’s cloud-based medical workflow.  The move solidifies Biotricity and B-Secur’s leadership in digital cardiovascular innovation,...

LAKE FOREST, Ill., Sept. 03, 2025 (GLOBE NEWSWIRE) — Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) announced that members of its management team will host investor meetings at two investor conferences in New York City during September 2025. Company management will host investor meetings at the HC Wainwright Conference on Wednesday, September 10, 2025, taking place at the Lotte New York Palace Hotel. Investors can register and request meetings via their HC Wainwright representative. The Company will also participate in investor meetings at the Lake Street Capital Markets BIG9 Conference, taking place September 11, 2025 at the Yale Club New York City. Investors can register and request meetings through their Lake Street representative. About Assertio Assertio is a pharmaceutical company with comprehensive commercial...

FLORHAM PARK, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the acceptance of an abstract for poster presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research taking place September 28-October 1 in Boston, Massachusetts. The poster presentation will highlight preclinical data from CLR 121225, the Company’s novel actinium-based radio conjugate alpha-emitter for treatment in hypoxic pancreatic ductal adenocarcinoma. “We are excited to present our poster at the AACR Special Conference on Pancreatic Cancer, further showcasing the potential of CLR 121225 for solid tumors,” said Jarrod Longcor, chief...

KISSIMMEE, Fla., Sept. 03, 2025 (GLOBE NEWSWIRE) — ECD Automotive Design proudly introduces Project Oliver, a 1996 Land Rover Defender D110 Signature Edition that redefines modern adventure. Purpose-built from the ground up, this hand-crafted Defender merges raw capability with elevated luxury, offering a seamless blend of rugged performance and refined design. Every detail, from its powerhouse V8 engine to its meticulously tailored interior, speaks to ECD’s philosophy of creating vehicles that reflect each client individually. Images for Oliver Video for Oliver At its core, Project Oliver is powered by a robust LT1 V8 engine, paired with a 10-speed automatic transmission, delivering commanding performance both on and off the road. Ready for sand and snow, this build has a central locking differential, heavy-duty axles, BREMBO...

WILMINGTON, Del., Sept. 03, 2025 (GLOBE NEWSWIRE) — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, or the “Company”), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., (“HOPE,” or the “Company”), an interventional psychiatry network wholly owned by NRx Pharmaceuticals, today announced that Jonathan Javitt, M.D., M.P.H., Chairman and Chief Executive Officer of NRx Pharmaceuticals, will participate in a fireside chat at H.C. Wainwright’s 27th Annual Global Investment Conference on Monday, September 8, 2025, from 4:30 to 5:00 PM ET. A webcast of the fireside chat will be available on the Events page of the Investors section of the Company’s website at https://ir.nrxpharma.com/events. A replay of the webcast will be available two hours after the...

WASHINGTON, Sept. 03, 2025 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, announced today the webcast link and change of date for management’s live presentation at the H.C. Wainwright 27th Annual Global Investment Conference in New York City, to Tuesday, September 9, 3:30 PM Eastern Time. Dr. Geoff Dow, 60 Degrees Pharma CEO, will present live and management will conduct one-on-one meetings during the conference. Event: H.C. Wainwright 27th Annual Global Investment ConferenceDate: September 9, 2025Time: 3:30 PM ETLocation: Lotte New York Palace HotelWebcast: Register About 60 Degrees Pharmaceuticals, Inc.60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing...

September 16 event to highlight preclinical data on the combination of FTI agents with multiple classes of targeted therapies October 18 event to review clinical data from the ESMO Congress 2025, including first clinical data from KO-2806 SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for cancer, today announced it will host two virtual investor and analyst events to spotlight its innovative farnesyl transferase inhibitor (FTI) program. These events will underscore Kura’s leadership in targeting cancer signaling pathways to address unmet needs in solid tumors and hematologic malignancies. Event Details:FTI Preclinical Program Review: Synergistic Combinations with Targeted TherapiesTuesday, September...

TORONTO, Sept. 03, 2025 (GLOBE NEWSWIRE) — Base Carbon Inc. (Cboe CA: BCBN) (OTCQX: BCBNF) with operations through its wholly-owned subsidiary, Base Carbon Capital Partners Corp. (“BCCPC”, together, with affiliates, “Base Carbon”, or the “Company”), is pleased to announce it has acquired additional expansion options for its India Afforestation, Reforestation and Revegetation Project. Additionally, the Company is pleased to announce it will host an investor town hall on Tuesday, September 30, 2025, at 11:00 a.m. Eastern Time. Options to Expand the India Afforestation, Reforestation, and Revegetation (ARR) Project The Company, through BCCPC, has been granted two contractual options to expand the India ARR Project at no additional cost to the Company. In securing the additional options, the Company modified its previously committed...